US9182409B2 - Mass spectrometry imaging method for detecting and quantifying a target molecule in a tissue sample - Google Patents

Mass spectrometry imaging method for detecting and quantifying a target molecule in a tissue sample Download PDF

Info

Publication number
US9182409B2
US9182409B2 US13/425,570 US201213425570A US9182409B2 US 9182409 B2 US9182409 B2 US 9182409B2 US 201213425570 A US201213425570 A US 201213425570A US 9182409 B2 US9182409 B2 US 9182409B2
Authority
US
United States
Prior art keywords
target analyte
tissue sample
sample
analyte
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US13/425,570
Other languages
English (en)
Other versions
US20120258485A1 (en
Inventor
Jonathan Stauber
Fabien Pamelard
David Bonnel
Grégory Hamm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imabiotech
Original Assignee
Imabiotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imabiotech filed Critical Imabiotech
Priority to US13/425,570 priority Critical patent/US9182409B2/en
Assigned to IMABIOTECH reassignment IMABIOTECH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: STAUBER, Jonathan, HAMM, GREGORY, LAVENTIE, BONNEL, PAMELARD, Fabien
Assigned to IMABIOTECH reassignment IMABIOTECH CORRECTIVE ASSIGNMENT TO CORRECT THE THIRD INVENTOR'S NAME FROM BONNEL LAVENTIE TO DAVID BONNEL PREVIOUSLY RECORDED ON REEL 028297 FRAME 0090. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ENTIRE INTEREST. Assignors: STAUBER, Jonathan, BONNEL, David, HAMM, GREGORY, PAMELARD, Fabien
Publication of US20120258485A1 publication Critical patent/US20120258485A1/en
Priority to US14/924,823 priority patent/US20160049284A1/en
Application granted granted Critical
Publication of US9182409B2 publication Critical patent/US9182409B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/02—Details
    • H01J49/10—Ion sources; Ion guns
    • H01J49/16—Ion sources; Ion guns using surface ionisation, e.g. field-, thermionic- or photo-emission
    • H01J49/161—Ion sources; Ion guns using surface ionisation, e.g. field-, thermionic- or photo-emission using photoionisation, e.g. by laser
    • H01J49/164—Laser desorption/ionisation, e.g. matrix-assisted laser desorption/ionisation [MALDI]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/0027—Methods for using particle spectrometers
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/0004—Imaging particle spectrometry

Definitions

  • the invention relates to a method for detecting and quantifying at least one targetmolecule (target analyte) in a sample by mass spectrometry. More particularly, the invention provides a method for detecting and quantifying a target analyte directly on the surface of a sample by using mass spectrometry imaging, in particular matrix-assisted laser desorption/ionization (MALDI) imaging.
  • MALDI matrix-assisted laser desorption/ionization
  • the invention can be applied in any field in which the quantification of a analyte in a sample is useful or necessary.
  • the invention can be applied, for example, in the pharmaceutical field to study the distribution and the pharmacokinetics of a drug in various biological tissues.
  • the invention can be applied in the field of agricultural chemistry, notably to evaluate the toxicity and the degradation of a analyte such as a herbicide in plants and/or the environment (soil, surrounding ground water, etc.).
  • Mass spectrometry is a technique widely known and used in chemical and biochemical analysis to detect and identify analytes of interest in a sample.
  • Molecular imaging by mass spectrometry such as MALDI imaging, has been developed in recent years, making it possible to visualize the distribution of analytes of interest directly on sections of biological tissue.
  • MALDI imaging by virtue of its high sensitivity, makes it possible to simultaneously visualize the distribution of a very large number of different analytes directly on the surface of a sample.
  • this technology makes it possible, for example, to compare the distribution of an analyte in various organs at various points of time during treatment.
  • the invention proposes a method generally using mass spectrometry, during a single analysis, to detect and quantify a target molecule (also referred to as a “target analyte”) in a sample.
  • a target molecule also referred to as a “target analyte”
  • the inventive method uses mass spectrometry imaging, which enables automated acquisition of a signal related to the mass spectrum of the target analyte, directly on the sample, in order to reconstruct images of the distribution and the quantity of said target analyte in the sample.
  • an extinction coefficient (TEC) for the target analyte, specific to each target analyte in a given sample is defined and integrated into the method.
  • TEC extinction coefficient
  • the TEC can then be used to normalize the signal obtained for said analyte, so that it is representative of its concentration, independently of the nature of the sample and its location in said sample. Direct quantification of the analyte from the mass spectrometry results obtained for the target analyte in the analyzed sample is thus made possible.
  • One object of the invention thus relates to a method for identifying and quantifying by mass spectrometry at least one target analyte in a sample, comprising the following steps:
  • the inventive method can apply to any type of sample that can be analyzed by a mass spectrometer, whether said sample is organic or inorganic.
  • the inventive method is also applicable to any type of support that can be used in mass spectrometry (slide, plate, membrane, etc.).
  • the method is thus particularly suited to the analysis of biological tissues.
  • tissue sections are prepared, typically on the order of several micrometers thick, and are deposited on a support, such as a slide, enabling their introduction into the mass spectrometer.
  • the inventive method can also be used for the analysis of environmental samples, such as samples of soil, water, plants, etc.
  • the sample can be deposited by any known technique, i.e., manually (for example by means of a pipette), or automatically (by using a spotting apparatus, or by spraying or sublimation, for example).
  • the sample can be diluted or treated before deposition on the sample support.
  • Step b) of analysis of the target analyte can be performed by any mass spectrometry method, notably using direct mass spectrometry (MS) or tandem mass spectrometry (MS n , MRM, SRM).
  • mass spectrometry method notably using direct mass spectrometry (MS) or tandem mass spectrometry (MS n , MRM, SRM).
  • the experimental parameters such as mass range and/or laser intensity, are advantageously set so as to optimize detection of the target analyte in terms of intensity, sensitivity and resolution.
  • step c various spectral characteristics can be used as the signal, notably the intensity of the peaks of the mass spectrum, the signal-to-noise ratio (S/N), the area of the peak, etc.
  • TEC extinction coefficient
  • the (TEC) is representative of the loss or gain in intensity of the target analyte's signal according to the nature of the sample and/or its location on the sample, compared to the signal of said analyte on an inert sample support.
  • the (TEC) is dependent on several factors, notably the sample's origin (animal, plant, bacterium, inorganic), the surface type (tissue, plant cell, metals, etc.), the chemical environment, the presence or absence of chemical treatment of the sample, etc.
  • the extinction coefficient of the analyte corresponds to the extinction coefficient of the tissue.
  • a preliminary histological, chemical or other study of the sample is carried out in order to define various areas of interest and to use them in the calculation of the TEC.
  • the TEC can be linked to a specific area of a sample, notably on a heterogeneous sample.
  • the TEC is obtained by the following relationship:
  • the signal corresponds to the spectral characteristic of the mass spectrum of the target analyte selected, for example the intensity of the peak of said analyte obtained on the mass spectrometer.
  • the spectral characteristic used for the analyte in the reference medium and on the sample must be the same.
  • the TEC is calculated using the same concentration of the target analyte in a reference medium and on the sample which is to be analyzed. It is also possible to use, in the place of the target analyte in a reference medium, an analyte that has similar physicochemical properties to those of the target analyte (e.g. an isotopically labeled target analyte).
  • the reference medium corresponds advantageously to the sample support alone.
  • the analyte is solubilized in a suitable medium (organic solvent, water or other) before deposition on the sample support. Deposition is followed by evaporation of the solvent, so that a dry deposition of the analyte on said support is obtained. It is the signal obtained for said analyte on the sample support that is then used for the TEC.
  • the TEC value is generally the mean of several measurements of the target analyte under the same conditions, in order to obtain a reliable coefficient.
  • the target analyte extinction coefficient is calculated only once for a given target analyte in a given type of sample, and is reused for each analysis of said target analyte in the given type of sample.
  • TEC target analyte extinction coefficient
  • the TEC value can be determined prior to each analysis.
  • the weighted signal measured in the sample is used to quantify said analyte.
  • the value of the weighted signal only depends on the concentration of the analyte. It is thus possible, for example, to determine the quantity of the target analyte by referring to a reference signal for the target analyte.
  • reference signal for the target analyte refers to a signal representative of a known concentration, independent of the nature of the sample and its position in the sample.
  • the reference signal can be a mean or median value (or a range of mean or median values) determined or established beforehand for a known quantity of a given analyte. It can also be a standard curve.
  • the reference signal is obtained by preparing a standard range with at least three different known concentrations of the target analyte (or of another analyte with physicochemical properties similar to those of the target analyte), in a reference medium such as a sample support on which the solubilized analyte has been deposited. If the analyte is deposited on a tissue sample, the analyte is advantageously adsorbed on said tissue after deposition and evaporation of the solubilization medium.
  • An internal standard different than the target analyte, can be introduced into the standard range in order to normalize the signal of said target analyte.
  • the analyte used as internal standard advantageously has physicochemical properties similar to those of the target analyte.
  • a constant concentration of this standard is added to the standard range of the target analyte before deposition.
  • the mass spectrum for each concentration is analyzed.
  • the spectral characteristic chosen as the comparison signal is read for each of said concentrations.
  • the selected associated spectral characteristic can be used to establish a calibration curve for said analyte. It is then sufficient to refer to this calibration curve to determine precisely the concentration in the analyzed sample.
  • the inventive method uses a mass spectrometry imaging technique requiring the use of a matrix, such as MALDI or matrix-enhanced secondary ion mass spectrometry (ME-SIMS) imaging, it is possible to use a standard analyte to obtain the reference signal of the target analyte.
  • a matrix such as MALDI or matrix-enhanced secondary ion mass spectrometry (ME-SIMS) imaging
  • a standard analyte of known molecular weight and at a known concentration, can be added to the MALDI matrix before use.
  • the resulting mixture is then deposited on the sample to be analyzed and on the support before analysis step b).
  • the signal obtained for the standard analyte corresponds to the reference signal for the target analyte.
  • the standard analyte is any analyte whose molecular weight is known.
  • a analyte with a molecular weight much different than the molecular weight of the target analyte is used as the standard analyte, so that the mass spectra obtained can be easily analyzed.
  • concentration of the standard analyte, taken up in a solubilization solution (aqueous or containing a solvent), is defined in order not to saturate the total signal.
  • the matrix/standard analyte mixture is deposited uniformly on the sample as well as on the periphery of the sample, i.e., on the sample support, to enable calculation of the TEC. During drying, co-crystallization of the mixture can be observed with the naked eye.
  • the signal obtained for the standard analyte whose concentration is known, is used to normalize the spectral characteristics of the target analyte in order to enable its quantification. It is thus also possible to take into account the effect of the matrix, described in further detail below.
  • a deuterated analyte i.e., a analyte labeled with deuterium, or a analyte labeled with any other suitable isotope, as the standard analyte.
  • a known concentration of the target analyte labeled with deuterium atoms can be added to the sample to be analyzed. If a matrix is used, the deuterated analyte can be mixed with the matrix. The resulting mixture is advantageously homogenized before being deposited uniformly on the sample and the sample support. Otherwise, a solution containing the deuterated analyte can be deposited on the sample.
  • the target analyte and its deuterated complement can then be evaluated simultaneously on the analyzed sample. Considering that their ionization will be identical, their analysis by mass spectrometry will result in the same signal with a difference in mass due to the presence of deuterium.
  • the signal obtained for the deuterated analyte corresponds to the reference signal for the target analyte. Since the concentration of the deuterated analyte is known, the ratio can then be calculated to yield a relative quantity.
  • the inventive method can advantageously be used with mass spectrometry imaging.
  • various ionization sources such as MALDI, laser desorption/ionization (LDI), desorption electrospray ionization (DESI), etc.
  • various types of analyzers such as time-of-flight (TOF), orbitrap, Fourier transform ion cyclotron resonance (FT-ICR), etc.
  • TOF time-of-flight
  • FT-ICR Fourier transform ion cyclotron resonance
  • This imaging technique makes it possible to quantify the target analyte directly on the ion density map obtained for the sample, corresponding to the spatial distribution of the target analyte in said sample.
  • the weighted signal on said ion density map can indeed be compared with a specific reference signal of the analyte of interest.
  • Certain mass spectrometry imaging techniques such as MALDI or ME-SIMS, require the sample to be analyzed to be covered beforehand by a matrix comprising small UV-absorbing organic molecules. This matrix enables the desorption and the ionization of the molecules present on the sample.
  • the inventive method can be used regardless of the matrix chosen.
  • These matrices are provided in solid form (crystallization on the sample) or liquid form and are ionic or non-ionic.
  • the matrix is chosen according to the mass range analyzed. They are generally prepared immediately before use in a solvent/aqueous solution mixture.
  • Several methods for depositing the matrix are possible, notably manual deposition using a pipette, which makes it possible to deposit a precise volume of matrix directly on the sample. It is also possible to deposit the matrix by spraying or by nebulization, wherein the matrix is sprayed or nebulized directly on the tissue by a robotic system or manually. Similarly, deposition by microdroplets wherein the matrix is spotted on the sample via piezoelectric, acoustic or syringe pump systems can be envisaged. It is also possible to deposit the matrix by sifting, in order to deposit the matrix in solid form.
  • the inventive method uses MALDI mass spectrometry imaging, a step of evaluating the homogeneity of the deposition of matrix on the sample can be expected.
  • the signal corresponding to the matrix used can indicate the quality/uniformity of the deposition of said matrix.
  • Matrix defects on the surface of the sample can then be correlated with the lack of detection or the loss of intensity of the signal of the target analyte in the sample studied.
  • the homogeneity of the matrix can be evaluated according to qualitative criteria by observing under an optical microscope the homogeneity of the deposition on the surface of the sample, and/or according to quantitative criteria by monitoring variations in the signal relative to the matrix itself on the sample.
  • the matrix is considered as an analyte itself whose signal during sample analysis is detected in the same way as the signal of the target analyte.
  • the signal of the matrix molecule is then compared with its reference signal.
  • the reference signal of the matrix corresponds in this case to the signal emitted by the matrix on a deposition of reference matrix, i.e., on a sample and on a sample support used specifically to measure the reference signal of the matrix.
  • the signal of the target analyte is validated and normalized to take into account variation in the quality of the matrix deposition, which can affect the matrix deposition's spectral characteristics.
  • This consideration of the matrix effect can be particularly advantageous when the monitoring of changes in the presence of a target analyte over time is desired, since matrix deposition quality can vary from one sample to the next.
  • the inventive method can be used to analyze any kind of molecule (target analyte), such as, for example, peptides, polypeptides, proteins, amino acids, nucleic acids, lipids, metabolites, etc., and, in general, any analyte that is active pharmaceutically or otherwise and that can be ionized by mass spectrometry.
  • target analyte such as, for example, peptides, polypeptides, proteins, amino acids, nucleic acids, lipids, metabolites, etc.
  • inventive method is particularly advantageous for the analysis of small analytes (notably drugs), i.e., analytes of molecular weight less than 2000 Da.
  • the target analyte is a protein of high molecular weight
  • Detection and quantification are then carried out for at least one of the peptides resulting from the enzymatic digestion and/or the chemical degradation/modification, representative of said protein.
  • trypsin can be used as an enzyme to cleave the target protein into several peptides identified beforehand.
  • Chemical pretreatment can consist of chemical hydrolysis, by acids or bases, a Maillard reaction, the formation of isopeptides or lysinoalanine, etc.
  • the sample it is possible to treat the sample to be analyzed with at least one solvent and/or at least one detergent prior to detection step b) so as to optimize detection of the target analyte.
  • washing with chloroform removes certain classes of lipids.
  • Washing with ethanol (FIG. 1 - b ) enables better detection of low-mass analytes.
  • the inventive method can also be used to detect and quantify at least two different target analytes on the same sample, simultaneously or sequentially.
  • the inventive method is particularly suited to the detection and quantification of target analytes on a section of biological, plant or animal tissue. Notably, analysis on a section of whole animal can make it possible to compare, on the same sample, the distribution of target analytes in various tissues of said animal.
  • the source data i.e., the TEC of the target analyte and the matrix effect
  • the source data can be normalized with a view to quantification by means of a computer program that integrates all or part of these factors.
  • This computer program, or data analysis software advantageously uses the TEC value weighted, if need be, by the matrix effect during the processing of the image in the case of mass spectrometry imaging.
  • Another object of the invention thus relates to a computer-readable data medium comprising computer-executable instructions, such as, for example, the reading of raw data resulting from mass spectrometry analysis, and/or determination of TECs and/or determination of the calibration curve, and/or normalization of the raw data using said TECs or said calibration curve in order to obtain a quantitative value for the target analyte.
  • these computer-executable instructions are suited to enable a computer system to execute at least step c) of the inventive method.
  • the data medium advantageously comprises at least one TEC database for at least one target analyte in at least two different sample types.
  • the database lists the TECs of at least one target analyte in various tissues of said sample.
  • the data medium can also comprise a database of the reference signal of at least one matrix used in mass spectrometry imaging.
  • a database of the reference signal of at least one matrix used in mass spectrometry imaging can also comprise a database of the reference signal of at least one matrix used in mass spectrometry imaging.
  • FIGS. 1A-1C Examples of the effect of two washings in direct analysis by mass spectrometry of heart tissue.
  • FIGS. 2A-2B MALDI-TOF mass spectrum of a digested model protein (bovine serum albumin with trypsin as digestion enzyme) on (a) a reference support (slide) and (b) tissue (rat liver).
  • a digested model protein bovine serum albumin with trypsin as digestion enzyme
  • tissue rat liver
  • YLYEIAR m/z 928 fragment
  • FIG. 3 A schematic representation of the principal steps of the inventive method, according to an example of implementation using mass spectrometry imaging.
  • FIGS. 4A-4B Methodology for calculating the tissue extinction coefficient in the study of the distribution of propranolol in whole-body mouse.
  • the internal standard propranolol, [M+H] + ion at m/z 260
  • FIGS. 5A-5B Methodology for calculating the tissue extinction coefficient of propranolol in the kidney.
  • FIG. 5A Optical image of the kidney, delimitation of several regions of interest (ROI) or areas of points of equal dimensions within the target organ.
  • FIG. 5B Table of mean intensities of the internal standard by ROI and between ROI (ROI mean).
  • FIGS. 6A-6B Table summarizing propranolol intensities by organ or by target areas.
  • FIG. 6B Histogram of propranolol intensities by organ or by target areas.
  • FIGS. 7A-7B Calculation of the tissue extinction coefficient.
  • FIG. 7A Mathematical relationship: Table summarizing TECs calculated for propranolol by target organ.
  • FIG. 7B Histogram of TECs calculated for propranolol by target organ.
  • FIGS. 8A-8C Determination of the calibration curve for the target analyte.
  • FIG. 8A Optical image of standard range depositions.
  • FIG. 8B Mass spectrometry image of the standard range, distribution of the target analyte.
  • FIG. 8C Table summarizing mean intensities of ROI of the standard range of the target analyte.
  • FIGS. 9A-9C Table summarizing mean intensities of ROI of the standard range of the target analyte.
  • FIG. 9B Graph of the calibration line.
  • FIG. 9C Correlation coefficient and straight-line equation.
  • FIGS. 10A-10C Quantification on the mass spectrometry image of the target analyte (propranolol), in a whole body.
  • FIG. 10A Optical image of a sagittal section of mice at 20 min post-injection of the target analyte and visualization of various organs or target areas (2-brain, 3-kidney, 4-lung, 5-liver, 6-heart).
  • FIG. 11 Quantification on the MS image of the target analyte, table summarizing the quantity of target analyte in the various organs. Explanation of the methodology for calculating the latter from mean intensities by organ and pixel with use of the TEC.
  • FIGS. 12A-12C Methodology for calculating the tissue extinction coefficient of olanzapine in the kidney.
  • FIG. 12A Optical image of a sagittal section of control mouse kidney.
  • FIG. 12B Mass spectrometry image of the distribution of the internal standard (olanzapine, [M+H] + ion at m/z 313.3) mixed with the matrix on and apart from the sample and intensity scale.
  • FIG. 12C Histogram of the TEC calculated for olanzapine in the kidney.
  • FIGS. 13A-13B Determination of the calibration curve for the target analyte.
  • FIG. 13A Mass spectrometry image of the standard range, distribution of the target analyte.
  • FIG. 13B Presentation of the calibration line relative to the MS image of olanzapine, its equation, its correlation coefficient and its limits of detection and of quantification in fmol/mm 2 .
  • FIGS. 14A-14B Quantification using the mass spectrometry image of the target analyte (olanzapine), in a kidney treated for 2 hours.
  • FIG. 14A Optical image of a sagittal section of mouse kidney at 2 hours post-administration of the target analyte.
  • the distribution of a drug (propranolol) in various organs of a mouse is studied by MALDI mass spectrometry imaging.
  • an imaging device other that MALDI could be used, such as, for example, the following sources: SIMS, DESI, DIOS, ICP, MALDI microscope, SNOM, SMALDI, LA-ICP, ESI (liquid extraction on tissue), MILDI, JEDI, ELDI, etc.
  • mice Male Swiss mice weighing 25-40 g (Charles River, France) were used. Propranolol taken up in 0.9% NaCl solution was injected by intravenous route at a concentration of 7.5 mg/kg.
  • the animals were sacrificed by CO 2 asphyxiation at 20 minutes post-injection.
  • the animals were then plunged into 100% isopentane solution cooled by liquid nitrogen for rapid freezing.
  • the animals were then stored at ⁇ 80° C.
  • the samples (control and dosed tissue) were sectioned into 20 ⁇ m-thick layers using a CM1510S cryostat (Leica Microsystems, Nanterre, France) cooled at ⁇ 26° C. The sections were then deposited on conductive ITO (indium tin oxide) slides (Bruker Daltonics, Bremen, Germany).
  • CM1510S cryostat Leica Microsystems, Nanterre, France
  • a DHB matrix was used for the analysis of the target analyte (propranolol) in the dosed tissue sections.
  • This matrix was prepared at a concentration of 40 mg/ml in methanol/0.1% TFA (1:1, v/v).
  • the matrix solution was deposited using the SunCollect spraying system (SunChrome, Germany).
  • HCCA matrix solution in ACN/0.1% TFA (7:3, v/v) was also prepared, to which a 10 pmol/ ⁇ l propranolol solution was added.
  • the matrix solution was deposited using the SunCollect spraying system (SunChrome, Germany) to cover the surface of the control tissue section.
  • the images were obtained using an AutoFlex Speed MALDI-TOF mass spectrometer (Bruker Daltonics, Bremen, Germany) equipped with a Smartbeam laser. The data was generated in positive reflectron mode. A total of 700 spectra were obtained for each spot with a 1000 Hz laser frequency and a 300 ⁇ 300 ⁇ m′ image spatial resolution on a mass range of 100 Da to 1000 Da. The FlexImaging version 2.1 software was used to reconstruct the images.
  • the propranolol solution used as an internal standard is mixed with the matrix above, prior to deposition of the resulting mixture on the control sample.
  • control sample is then analyzed by mass spectrometry imaging in order to obtain an image of the distribution of the internal standard on the control sample and on the support slide ( FIG. 3B ).
  • the various organs of interest can advantageously be located beforehand by optical imaging of the control sample ( FIG. 3A ).
  • ROI regions of interest
  • the intensity of the peaks of the mass spectrum was selected as the reference signal.
  • the mean intensities of the internal standard for each ROI and each organ of interest were recorded.
  • a mean intensity was calculated from the intensity obtained for all the corresponding ROI. This mean ROI will be used to calculate the extinction coefficient of propranolol in each organ studied.
  • FIG. 5 shows a schematic diagram of these various steps for the kidney.
  • FIG. 6A summarizes the mean ROI obtained for propranolol in the various organs of interest of the control sample
  • FIG. 6B shows the histogram of the corresponding signal intensities obtained.
  • the TEC can then be calculated ( FIG. 7A ) using the mean ROI values from the slide and from each organ, according to the mathematical formula:
  • TEC Int ⁇ ( slide ) x Int ⁇ ( tissue ) x
  • the associated signal in the kidney is divided by nearly 13 compared to the expected signal, i.e., the signal on the slide.
  • the signal is only divided by 4.82 in the liver and 7.96 in the heart.
  • the signal is divided by less than 8 in the lungs and by 6.18 in the brain.
  • the reference signal for the target analyte corresponds to the signal obtained for a standard range of seven concentrations of propranolol.
  • the mass spectrometry image obtained for these various concentrations ( FIG. 8B ) is normalized for all points in the range using an ROI of identical dimensions, from which a mean reference intensity, or reference signal, for propranolol is defined.
  • a calibration line ( FIG. 9B ) can then be plotted, thereafter making it possible during analysis to correlate any signal intensity obtained for propranolol with a concentration by pixel.
  • the signal intensity obtained for propranolol is increased in each organ of interest as a function of the TEC calculated for each.
  • a mass spectrometry image of the section of the whole animal is obtained in which signal intensity corresponds to absolute intensity, i.e., intensity of the propranolol concentration alone ( FIG. 10C ).
  • This image can be correlated with the calibration line previously calculated for propranolol in order to determine the quantity of propranolol in the sample directly by visualizing the image.
  • propranolol is virtually absent from the liver and lungs, in contrast to the brain where the distribution of propranolol is greatest with a total quantity of the target analyte of about 5 ng. Propranolol is also observed in the kidneys and lungs, with quantities ranging from 1.28 ng to 2 ng.
  • mice Male Swiss mice weighing 25-40 g (Charles River, France) were used. Olanzapine was administered orally at a concentration of 8 mg/kg.
  • the animals were sacrificed by CO 2 asphyxiation at 2 hours post-administration.
  • the animals were then plunged into 100% isopentane solution cooled by liquid nitrogen for rapid freezing.
  • the animals were then stored at ⁇ 80° C.
  • HCCA matrix was used for the analysis of the target analyte (olanzapine) in the tissue sections. This matrix was prepared at a concentration of 10 mg/ml in ACN/0.1% TFA (7:3, v/v). The matrix solution was deposited using the SunCollect spraying system.
  • a range of dilutions of olanzapine taken up in DMSO was deposited manually using a pipette (1 ⁇ l per point) prior to deposition of the matrix. This range of dilution extends from 60 pmol/ ⁇ l to 1 pmol/ ⁇ l and includes seven points.
  • a 10 mg/ml HCCA matrix solution in ACN/0.1% TFA (7:3, v/v) was also prepared, to which a 10 pmol/ ⁇ l olanzapine solution was added.
  • the matrix solution was deposited using the SunCollect spraying system to cover the surface of the tissue section.
  • the images were obtained in a manner identical to example 1, but with a 200 ⁇ 200 ⁇ m 2 image spatial resolution.
  • the olanzapine solution used as an internal standard is mixed with the matrix above, prior to deposition of the resulting mixture on the control sample.
  • control sample is then analyzed by mass spectrometry imaging in order to obtain an image of the distribution of the internal standard on the control sample and on the support slide ( FIG. 12B ).
  • the optical image of the control sample presented in FIG. 12A makes it possible to visualize the organ of interest, i.e., the kidney.
  • ROI regions of interest
  • the TEC ( FIG. 12C ) is calculated according to same methodology as example 1. It is thus observed that, for the same concentration of olanzapine, the associated signal in the kidney is divided by nearly 22.2 compared to the expected signal, i.e., the signal on the slide.
  • the reference signal for olanzapine represented in FIG. 13 , corresponds to the signal obtained for a standard range of seven concentrations of olanzapine.
  • the mass spectrometry image obtained for these various concentrations ( FIG. 13A ) is normalized for all points in the range using an ROI of identical dimensions, from which a mean reference intensity, or reference signal, for olanzapine is defined.
  • a calibration line ( FIG. 13B ) can then be plotted, thereafter making it possible during analysis to correlate any signal intensity obtained for olanzapine with a concentration in pmol per mm 2 .
  • a mass spectrometry image of the section of kidney is thus obtained, on which olanzapine is localized through the detection of the m/z 313.3 ion ( FIG. 14B ) primarily in the medulla.
  • the signal intensity obtained for olanzapine is normalized in the kidney as a function of the TEC calculated beforehand. This data can then be correlated with the calibration line previously calculated for olanzapine in order to obtain its total concentration in the kidney in pmol/mm 2 .
  • a mean concentration of olanzapine (over three experiments) of 41.1 ⁇ g/g tissue can be calculated.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Plasma & Fusion (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US13/425,570 2011-03-21 2012-03-21 Mass spectrometry imaging method for detecting and quantifying a target molecule in a tissue sample Active 2033-12-29 US9182409B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/425,570 US9182409B2 (en) 2011-03-21 2012-03-21 Mass spectrometry imaging method for detecting and quantifying a target molecule in a tissue sample
US14/924,823 US20160049284A1 (en) 2011-03-21 2015-10-28 Method for detecting and quantifying a target analyte in a sample

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR1152334A FR2973112B1 (fr) 2011-03-21 2011-03-21 Procede de detection et de quantification d'une molecule cible dans un echantillon
FR1152334 2011-03-21
US201161539681P 2011-09-27 2011-09-27
US13/425,570 US9182409B2 (en) 2011-03-21 2012-03-21 Mass spectrometry imaging method for detecting and quantifying a target molecule in a tissue sample

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/924,823 Continuation US20160049284A1 (en) 2011-03-21 2015-10-28 Method for detecting and quantifying a target analyte in a sample

Publications (2)

Publication Number Publication Date
US20120258485A1 US20120258485A1 (en) 2012-10-11
US9182409B2 true US9182409B2 (en) 2015-11-10

Family

ID=44119805

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/425,570 Active 2033-12-29 US9182409B2 (en) 2011-03-21 2012-03-21 Mass spectrometry imaging method for detecting and quantifying a target molecule in a tissue sample
US14/924,823 Abandoned US20160049284A1 (en) 2011-03-21 2015-10-28 Method for detecting and quantifying a target analyte in a sample

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/924,823 Abandoned US20160049284A1 (en) 2011-03-21 2015-10-28 Method for detecting and quantifying a target analyte in a sample

Country Status (11)

Country Link
US (2) US9182409B2 (ja)
EP (1) EP2689251B1 (ja)
JP (1) JP6145085B2 (ja)
KR (1) KR102003825B1 (ja)
CN (2) CN103620413B (ja)
AU (1) AU2012230422B2 (ja)
CA (1) CA2830291C (ja)
DK (1) DK2689251T3 (ja)
ES (1) ES2745648T3 (ja)
FR (1) FR2973112B1 (ja)
WO (1) WO2012126873A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160335473A1 (en) * 2014-01-10 2016-11-17 Imabiotech Method for processing molecular imaging data and corresponding data server
US9645138B2 (en) 2013-02-25 2017-05-09 Imabiotech Method to evaluate the tissue targeting of a molecule of interest

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2976076B1 (fr) 2011-05-31 2015-02-27 Imabiotech Procede de detection et de quantification d'une molecule cible dans un tissu
CN103901093B (zh) * 2014-03-13 2017-01-04 华东理工大学 制备亲疏水相间的微阵列芯片及其用于质谱成像定量分析的方法
CN104198572A (zh) * 2014-08-26 2014-12-10 宜昌捷诺威医药科技有限公司 用于检测脂类组合物c18：2ce和sm22：0含量的方法
CN105572212B (zh) * 2014-10-14 2018-12-07 中国科学院大连化学物理研究所 一种基于可视化质谱信息的生晒参和红参快速识别方法
CN105574474B (zh) * 2014-10-14 2019-03-12 中国科学院大连化学物理研究所 一种基于质谱信息的生物特征图像识别方法
US10441668B2 (en) 2014-12-08 2019-10-15 University Health Network System and method for enhanced mass spectrometry imaging
CA2965435C (en) * 2014-12-17 2022-05-17 Ventana Medical Systems, Inc. Accurately calculating acoustic time-of-flight
EP3254301B1 (en) * 2015-02-06 2021-03-31 DH Technologies Development Pte. Ltd. Lipid screening platform allowing a complete solution for lipidomics research
WO2016137398A1 (en) * 2015-02-25 2016-09-01 Agency for Science,Technology and Research Device and method for detecting target molecules
CA2981085A1 (en) * 2015-03-06 2016-09-15 Micromass Uk Limited Spectrometric analysis
KR101746535B1 (ko) 2015-07-27 2017-06-13 서강대학교산학협력단 Maldi-tof 질량분석방법을 이용한 고분자내 올리고머의 정량분석 방법
WO2017049403A1 (en) * 2015-09-22 2017-03-30 University Health Network System and method for optimized mass spectrometry analysis
BR112018010156A8 (pt) * 2015-11-20 2019-02-26 Treat4Life Ab método para análise de adesão de fármaco em uma amostra de tecido
CA3066002C (en) 2016-06-10 2022-10-18 University Health Network Soft ionization system and method of use thereof
KR102535976B1 (ko) * 2016-06-13 2023-05-23 건국대학교 산학협력단 형광이미지 및 질량 분석을 이용한 의약품의 생체분포도를 상호보완적으로 확인하는 방법
JP7125418B2 (ja) * 2017-04-13 2022-08-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 蛍光画像における標的分子密度決定
JP7211980B2 (ja) * 2017-06-12 2023-01-24 プロテイン ダイナミック ソリューションズ インコーポレイテッド 結晶及び結晶化を分析する方法及びシステム
SE1750924A1 (sv) * 2017-07-14 2018-10-02 A method for analyzing the 3d structure of biomolecules
US20220137027A1 (en) * 2019-01-22 2022-05-05 Imabiotech Method for evaluating molecular changes related to a molecule effect in a biological sample
US11887827B2 (en) 2019-04-24 2024-01-30 Shimadzu Corporation Imaging analysis device

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1580682A2 (en) 2004-03-17 2005-09-28 Sysmex Corporation Diagnostic support system for diabetes and storage medium
WO2011073740A1 (en) 2009-12-15 2011-06-23 Centre National De La Recherche Scientifique (Cnrs) Matrices for mass spectrometry imaging

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR892101A0 (en) * 2001-11-16 2001-12-13 Proteome Systems Ltd High resolution automated maldi data analysis
AU2003287017B2 (en) * 2002-10-03 2011-10-06 Norman Leigh Anderson High sensitivity quantitation of peptides by mass spectrometry
KR101035213B1 (ko) * 2005-11-08 2011-05-18 도호쿠 다이가쿠 질량 분석계를 사용한 막 단백질의 정량 방법
US8596045B2 (en) * 2007-02-21 2013-12-03 Volvo Lastvagnar Ab On-board-diagnosis method for an exhaust aftertreatment system and on-board-diagnosis system for an exhaust aftertreatment system
WO2008126151A1 (ja) * 2007-04-04 2008-10-23 Shimadzu Corporation 質量分析データ解析方法及び装置
JP2009009684A (ja) * 2007-06-01 2009-01-15 Fujifilm Corp 光情報記録媒体および情報記録方法
US8384021B2 (en) * 2009-04-10 2013-02-26 Canon Kabushiki Kaisha Method of forming mass image
JP5478998B2 (ja) * 2009-09-02 2014-04-23 公益財団法人野口研究所 分析方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1580682A2 (en) 2004-03-17 2005-09-28 Sysmex Corporation Diagnostic support system for diabetes and storage medium
WO2011073740A1 (en) 2009-12-15 2011-06-23 Centre National De La Recherche Scientifique (Cnrs) Matrices for mass spectrometry imaging

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Hamm et al. "Quantitative mass spectrometry imaging of propranolol and olanzapine using tissue extinction calculation as normalization factor", J. Proteomics, 2012, v. 75, pp. 4952-4961. *
Hare, D. et al. "Three-dimensional elemental bio-imaging of Fe, Zn, Cu, Mn and P in a 6-hydroxydopamine lesioned mouse brain" Metallomics, Nov. 2010, pp. 745-753, vol. 2, No. 11.
Kaletas, B. K. et al. "Sample preparation issues for tissue imaging by imaging MS" Proteomics, 2009, pp. 2622-2633, vol. 9.
Tech Tip #6 Thermoscientific, "Extinction coefficients", 2008, pp. 1-3. *
Zabet-Moghaddam, M. et al. "Qualitative and quantitative analysis of lower molecular weight compounds by ultraviolet matrix-assisted laser desorption/ionization mass spectrometry using ionic liquid matrices" Rapid Communications in Mass Spectrometry, 2004, pp. 141-148, vol. 18.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9645138B2 (en) 2013-02-25 2017-05-09 Imabiotech Method to evaluate the tissue targeting of a molecule of interest
US20160335473A1 (en) * 2014-01-10 2016-11-17 Imabiotech Method for processing molecular imaging data and corresponding data server
US10013598B2 (en) * 2014-01-10 2018-07-03 Imabiotech Method for processing molecular imaging data and corresponding data server

Also Published As

Publication number Publication date
KR20140037065A (ko) 2014-03-26
ES2745648T3 (es) 2020-03-03
US20160049284A1 (en) 2016-02-18
FR2973112A1 (fr) 2012-09-28
EP2689251B1 (en) 2019-06-19
FR2973112B1 (fr) 2018-05-25
CN107179349A (zh) 2017-09-19
CN103620413A (zh) 2014-03-05
DK2689251T3 (da) 2019-09-23
EP2689251A1 (en) 2014-01-29
AU2012230422A1 (en) 2013-10-10
JP2014508946A (ja) 2014-04-10
WO2012126873A1 (en) 2012-09-27
CN103620413B (zh) 2017-12-01
US20120258485A1 (en) 2012-10-11
AU2012230422B2 (en) 2016-11-10
CA2830291A1 (en) 2012-09-27
CA2830291C (en) 2020-06-30
JP6145085B2 (ja) 2017-06-07
KR102003825B1 (ko) 2019-07-25

Similar Documents

Publication Publication Date Title
US9182409B2 (en) Mass spectrometry imaging method for detecting and quantifying a target molecule in a tissue sample
Rzagalinski et al. Quantification of low molecular weight compounds by MALDI imaging mass spectrometry–A tutorial review
Castellino et al. MALDI imaging mass spectrometry: bridging biology and chemistry in drug development
Hamm et al. Quantitative mass spectrometry imaging of propranolol and olanzapine using tissue extinction calculation as normalization factor
Pirman et al. Identifying tissue-specific signal variation in MALDI mass spectrometric imaging by use of an internal standard
Guenther et al. AP-MALDI imaging of neuropeptides in mouse pituitary gland with 5 μm spatial resolution and high mass accuracy
Barry et al. Assessing drug and metabolite detection in liver tissue by UV-MALDI and IR-MALDESI mass spectrometry imaging coupled to FT-ICR MS
Specker et al. Identification of phosphatidylcholine isomers in imaging mass spectrometry using gas-phase charge inversion ion/ion reactions
Tomlinson et al. Using a single, high mass resolution mass spectrometry platform to investigate ion suppression effects observed during tissue imaging
Ryan et al. Protein identification in imaging mass spectrometry through spatially targeted liquid micro‐extractions
Randall et al. MALDI imaging of liquid extraction surface analysis sampled tissue
JP6170911B2 (ja) 組織中のターゲット分子を検出および定量するための方法
Ye et al. Probing neuropeptide signaling at the organ and cellular domains via imaging mass spectrometry
Flanigan IV et al. Quantitative measurements of small molecule mixtures using laser electrospray mass spectrometry
Fernández-Vega et al. Optimization of a MALDI-imaging protocol for studying adipose tissue-associated disorders
Nilsson et al. Mass spectrometry of peptides in neuroscience
Pu et al. High-throughput intact protein analysis for drug discovery using infrared matrix-assisted laser desorption electrospray ionization mass spectrometry
Heeren et al. Quality of surface: the influence of sample preparation on MS-based biomolecular tissue imaging with MALDI-MS and (ME-) SIMS
Minerva et al. Direct profiling and identification of peptide expression differences in the pancreas of control and ob/ob mice by imaging mass spectrometry
DeLaney et al. Advances in high‐resolution maldi mass spectrometry for neurobiology
Chen et al. Compound property optimization in drug discovery using quantitative surface sampling micro liquid chromatography with tandem mass spectrometry
Martínez-Gardeazabal et al. Mass spectrometry for the advancement of lipid analysis in Alzheimer’s research
Villacob et al. Collision-Induced Unfolding, Tandem MS, Bottom-up Proteomics, and Interactomics for Identification of Protein Complexes in Native Surface Mass Spectrometry
Liang et al. Enhancing Spatial Resolution in Tandem Mass Spectrometry Ion/Ion Reaction Imaging Experiments through Image Fusion
Goto-Inoue et al. Imaging mass spectrometry of glycolipids

Legal Events

Date Code Title Description
AS Assignment

Owner name: IMABIOTECH, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STAUBER, JONATHAN;PAMELARD, FABIEN;LAVENTIE, BONNEL;AND OTHERS;SIGNING DATES FROM 20120511 TO 20120518;REEL/FRAME:028297/0090

AS Assignment

Owner name: IMABIOTECH, FRANCE

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE THIRD INVENTOR'S NAME FROM BONNEL LAVENTIE TO DAVID BONNEL PREVIOUSLY RECORDED ON REEL 028297 FRAME 0090. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ENTIRE INTEREST;ASSIGNORS:STAUBER, JONATHAN;PAMELARD, FABIEN;BONNEL, DAVID;AND OTHERS;SIGNING DATES FROM 20120511 TO 20120518;REEL/FRAME:028323/0553

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
CC Certificate of correction
MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 8